Pluri Inc.

Pluri Inc. develops proprietary platforms to manufacture scalable cell-based products using a patented 3D expansion system. The company’s core expertise lies in human placental adherent stromal cells for regenerative medicine but has expanded into agricultural biotechnology (PluriAgtech) and food technology (e.g., developing cell-cultured coffee). In January 2024, it launched a CDMO division to provide contract development/manufacturing services for the growing global market of advanced therapies. The company operates GMP-certified facilities supporting both its own pipeline and external partnerships. Recent years have seen diversification beyond traditional biotech into sustainability-focused sectors like agri-food tech.[1][2][3][4]